vs

Side-by-side financial comparison of AMERICAN REALTY INVESTORS INC (ARL) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.

AMERICAN REALTY INVESTORS INC is the larger business by last-quarter revenue ($13.0M vs $8.4M, roughly 1.6× Immunovant, Inc.). AMERICAN REALTY INVESTORS INC runs the higher net margin — 75.2% vs -899.0%, a 974.2% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 8.1%).

Weingarten Realty Investors was a real estate investment trust that invested in shopping centers, primarily in the Southern United States and primarily with grocery stores as the anchor stores. In August 2021, the company was acquired by Kimco Realty.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

ARL vs IMVT — Head-to-Head

Bigger by revenue
ARL
ARL
1.6× larger
ARL
$13.0M
$8.4M
IMVT
Growing faster (revenue YoY)
IMVT
IMVT
+132.7% gap
IMVT
140.7%
8.1%
ARL
Higher net margin
ARL
ARL
974.2% more per $
ARL
75.2%
-899.0%
IMVT

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
ARL
ARL
IMVT
IMVT
Revenue
$13.0M
$8.4M
Net Profit
$9.8M
$-75.3M
Gross Margin
Operating Margin
-23.3%
-896.2%
Net Margin
75.2%
-899.0%
Revenue YoY
8.1%
140.7%
Net Profit YoY
6175.8%
-26.7%
EPS (diluted)
$0.60
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARL
ARL
IMVT
IMVT
Q4 25
$13.0M
Q3 25
$12.8M
Q2 25
$12.2M
Q1 25
$12.0M
Q4 24
$12.0M
Q3 24
$11.6M
Q2 24
$11.8M
Q1 24
$11.9M
$8.4M
Net Profit
ARL
ARL
IMVT
IMVT
Q4 25
$9.8M
Q3 25
$129.0K
Q2 25
$2.8M
Q1 25
$3.0M
Q4 24
$-161.0K
Q3 24
$-17.5M
Q2 24
$1.2M
Q1 24
$1.8M
$-75.3M
Operating Margin
ARL
ARL
IMVT
IMVT
Q4 25
-23.3%
Q3 25
-12.3%
Q2 25
-8.3%
Q1 25
-6.8%
Q4 24
-14.8%
Q3 24
-17.8%
Q2 24
-10.8%
Q1 24
-12.7%
-896.2%
Net Margin
ARL
ARL
IMVT
IMVT
Q4 25
75.2%
Q3 25
1.0%
Q2 25
23.2%
Q1 25
24.7%
Q4 24
-1.3%
Q3 24
-150.4%
Q2 24
9.9%
Q1 24
14.7%
-899.0%
EPS (diluted)
ARL
ARL
IMVT
IMVT
Q4 25
$0.60
Q3 25
$0.01
Q2 25
$0.18
Q1 25
$0.18
Q4 24
$-0.01
Q3 24
$-1.08
Q2 24
$0.07
Q1 24
$0.11
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARL
ARL
IMVT
IMVT
Cash + ST InvestmentsLiquidity on hand
$89.1M
$635.4M
Total DebtLower is stronger
$214.4M
Stockholders' EquityBook value
$617.4M
$617.8M
Total Assets
$1.1B
$666.4M
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARL
ARL
IMVT
IMVT
Q4 25
$89.1M
Q3 25
$82.8M
Q2 25
$73.5M
Q1 25
$88.7M
Q4 24
$99.7M
Q3 24
$131.6M
Q2 24
$127.5M
Q1 24
$130.9M
$635.4M
Total Debt
ARL
ARL
IMVT
IMVT
Q4 25
$214.4M
Q3 25
$227.0M
Q2 25
$216.0M
Q1 25
$201.7M
Q4 24
$185.4M
Q3 24
$183.8M
Q2 24
$181.0M
Q1 24
$181.8M
Stockholders' Equity
ARL
ARL
IMVT
IMVT
Q4 25
$617.4M
Q3 25
$607.8M
Q2 25
$607.8M
Q1 25
$604.9M
Q4 24
$601.8M
Q3 24
$602.2M
Q2 24
$619.9M
Q1 24
$618.8M
$617.8M
Total Assets
ARL
ARL
IMVT
IMVT
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Q1 24
$1.0B
$666.4M
Debt / Equity
ARL
ARL
IMVT
IMVT
Q4 25
0.35×
Q3 25
0.37×
Q2 25
0.36×
Q1 25
0.33×
Q4 24
0.31×
Q3 24
0.31×
Q2 24
0.29×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARL
ARL
IMVT
IMVT
Operating Cash FlowLast quarter
$-5.6M
$-59.7M
Free Cash FlowOCF − Capex
$-59.8M
FCF MarginFCF / Revenue
-714.4%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
-0.57×
TTM Free Cash FlowTrailing 4 quarters
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARL
ARL
IMVT
IMVT
Q4 25
$-5.6M
Q3 25
$8.0M
Q2 25
$-2.9M
Q1 25
$-7.4M
Q4 24
$1.1M
Q3 24
$13.5M
Q2 24
$-503.0K
Q1 24
$3.9M
$-59.7M
Free Cash Flow
ARL
ARL
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-59.8M
FCF Margin
ARL
ARL
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-714.4%
Capex Intensity
ARL
ARL
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
1.8%
Cash Conversion
ARL
ARL
IMVT
IMVT
Q4 25
-0.57×
Q3 25
61.81×
Q2 25
-1.03×
Q1 25
-2.50×
Q4 24
Q3 24
Q2 24
-0.43×
Q1 24
2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons